All In Biotech

Drug Trial Radar · NCT02074800

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

A Phase 1, Randomized Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Feb 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Jun 2008

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of Part 1 of this study is to assess the safety and tolerability of 2 dose levels (1.4 and 2.8 mg/kg) of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328. The purpose of Part 2 of this study is to access the pharmacokinetics (what the body does to the study medication) comparability of the 1.4 mg/kg dose of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328.

Conditions

  • Healthy

Interventions

  • CNTO 328 (Sp2/0-derived)Drug

    Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

  • CNTO 328 (CHO-derived)Drug

    Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

  • PlaceboDrug

    Participants will receive a single-dose of matching placebo intravenously in Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events as a measure of safety and tolerability in Part 1Time frame: Up to Day 199
  2. Maximum observed serum concentration (Cmax) of CNTO 328 in Part 2Time frame: Day 1 (predose, end of infusion, and postdose at Hours 1, 2, 4, and 8), Days 2 to 6, and Days 8, 15, 22, 29, 36, 43, 50, 71, and 85
  3. Area under the serum concentration-time curve from Day 0 to Day 84 (AUC 0-84D) of CNTO 328 in Part 2Time frame: Day 1 (predose, end of infusion, and postdose at Hours 1, 2, 4, and 8), Days 2 to 6, and Days 8, 15, 22, 29, 36, 43, 50, 71, and 85

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Neptune City, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.